Cero Therapeutics Holdings Inc. has announced the exercise of an option for additional Series D financing. The company issued more shares of its Series D Preferred Stock to institutional investors, generating approximately $750,000 in gross proceeds. This funding will support the advancement of their clinical programs, including the recent FDA IND allowances in liquid and solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.